AI Generated
Apr 12, 2026, 12:56
Chokri Ben Lamine: Clinical Dosing and Special Populations Guide for Apixaban
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Apixaban Pearls (Indications, Dosing plus, and Special Populations)
Mechanism
- Leads to Direct Factor Xa inhibitor leads to decrease thrombin generation
Indications
- VTE treatment (DVT/PE)
- Extended VTE prophylaxis
- Stroke prevention in AF (NVAF)
- Post-op prophylaxis (hip/knee)
Dosing (Adults)
Acute VTE
- 10 mg twice daily for 7 days
- Then 5 mg twice daily
Extended VTE
- 2.5 mg twice daily after at least 6 months of treatment
AF stroke prevention
- 5 mg twice daily
Dose reduction AF
- 2.5 mg twice daily if ≥2 of the following are present:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥133 µmol/L (≈1.5 mg/dL)
Post-operative prophylaxis
- Hip replacement: 2.5 mg twice daily for 35 days
- Knee replacement: 2.5 mg twice daily for 12 days
Special Populations
Renal impairment
- Creatinine clearance ≥30 mL/min: standard dosing
- Creatinine clearance 15–29 mL/min: use with caution (dose reduction in atrial fibrillation)
- Creatinine clearance <15 mL/min or dialysis: limited evidence; avoid use (prefer warfarin)
Hepatic disease
- Mild (Child–Pugh A): use without dose adjustment
- Moderate (Child–Pugh B): use with caution
- Severe (Child–Pugh C): not recommended / contraindicated
Cancer-associated VTE
- Preferred option: DOAC in many patients (vs LMWH, depending on bleeding risk and cancer type)
- Avoid: if active gastrointestinal or genitourinary lesions due to increased bleeding risk
Obesity
- BMI >40 kg/m² or weight >120 kg: use with caution
- Consider drug level monitoring (anti–Xa activity) or alternative anticoagulation (LMWH or warfarin)
Elderly
- Increased bleeding risk
- Assess carefully for dose reduction criteria and comorbidities
Pregnancy
- Not recommended
- Use low-molecular-weight heparin (LMWH)
Breastfeeding
- Not recommended (insufficient safety data)
Antiphospholipid syndrome (APS)
- Not recommended, particularly in triple-positive APS
- Prefer warfarin
Drug interactions
- Strong CYP3A4/P-gp inhibitors (e.g., azoles, clarithromycin): increased bleeding risk
- Strong inducers (e.g., rifampin, carbamazepine): reduced efficacy
Bleeding management
- Specific reversal agent: andexanet alfa (if available)
- If unavailable: prothrombin complex concentrate (PCC)
Key pearl
- Apixaban has one of the safest bleeding profiles among direct oral anticoagulants in many hematology patients.”
Find more posts featuring Chokri Ben Lamine on Hemostasis Today.
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly
-
May 27, 2026, 15:59Sara Trompeter: Improving Transfusion Safety Through Advanced Blood Matching in SCD
-
May 27, 2026, 15:58Hassan Raza: Global Advocacy for People With Bleeding Disorders Must Continue Beyond Adoption
-
May 27, 2026, 15:43Aryabhatta Sadhu: Effective Hemotherapy Beyond Transfusion
-
May 27, 2026, 15:38Wolfgang Miesbach: How Haemophilia Care Has Evolved in China